The Medicines Co. begins trial enrollment for cangrelor

By Elaine Rigoli

Tampa, Fla., April 4 - The Medicines Co. has enrolled its first patients in phase 3 clinical trials evaluating cangrelor, a fast-acting, reversible, intravenous anti-platelet agent for preventing platelet activation and aggregation during the clotting process.

If the trials are successfully completed and cangrelor receives regulatory clearance, the company said cangrelor will be the first IV platelet inhibitor to market that binds directly to the P2Y12 receptor, a clinically validated target to treat or prevent arterial thrombosis in patients undergoing percutaneous coronary intervention (PCI).

The phase 3 program is comprised of two multinational trials to evaluate cangrelor's effectiveness and safety in preventing ischemic events in patients who require PCI, according to a news release.

The first trial to enroll is called Champion PCI and has a planned enrollment estimated at 9,000 patients.

The second trial, expected to begin in late 2006, is called Champion Platform and has planned enrollment estimated at 4,000 patients.

The entire phase 3 clinical trial patient enrollment will be completed in 18 to 24 months, the release said.

Based in Parsippany, N.J., The Medicines Co. develops products for acute hospital care.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.